Kalydeco Evrópusambandið - íslenska - EMA (European Medicines Agency)

kalydeco

vertex pharmaceuticals (ireland) limited - ivacaftor - cystic fibrosis - Önnur öndunarfæri - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 og 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Mirvaso Evrópusambandið - íslenska - EMA (European Medicines Agency)

mirvaso

galderma international - brimonidintartrat - húðsjúkdómar - aðrar húðsjúkdómar - mirvaso er ætlað til meðferðar við geðrofsroði rósroða hjá fullorðnum sjúklingum.

Metvix Krem 160 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

metvix krem 160 mg/g

galderma nordic ab - methyl aminolevulinate hydrochloride - krem - 160 mg/g

Differin Hlaup 1 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

differin hlaup 1 mg/g

galderma nordic ab - adapalenum inn - hlaup - 1 mg/g

Soolantra Krem 10 mg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

soolantra krem 10 mg/g

galderma nordic ab - ivermectinum inn - krem - 10 mg/g

Epiduo Hlaup 0,1 % / 2,5 % Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

epiduo hlaup 0,1 % / 2,5 %

galderma nordic ab - adapalenum inn; benzoylis peroxidum - hlaup - 0,1 % / 2,5 %

Aklief Krem 50 míkróg/g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

aklief krem 50 míkróg/g

galderma nordic ab - trifarotenum - krem - 50 míkróg/g

Oracea Hart hylki með breyttan losunarhraða 40 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

oracea hart hylki með breyttan losunarhraða 40 mg

galderma nordic ab - doxycyclinum inn - hart hylki með breyttan losunarhraða - 40 mg

Talmanco (previously Tadalafil Generics) Evrópusambandið - íslenska - EMA (European Medicines Agency)

talmanco (previously tadalafil generics)

viatris limited - tadalafil - háþrýstingur, lungnabólga - Þvaglát - talmanco er ætlað í fullorðnir fyrir meðferð lungum slagæð háan blóðþrýsting (pah) flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma.

Soluprick SQ (Tree Pollen) Húðstungupróf, lausn 10 HEP Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

soluprick sq (tree pollen) húðstungupróf, lausn 10 hep

alk-abelló a/s - corylus avellana; alnus glutinosa (alder); alnus incana; betula verrucosa - húðstungupróf, lausn - 10 hep